Feedback / Questions
zovaglutide (ZT002) - Beijing QL Biopharma
https://www.prnewswire.com/news-releases/ql-biopharm-reports-phase-2-results-of-a-monthly-dose-study-evaluating-zovaglutide-a-novel-extended-half-life-glp-1-receptor-agonist-at-easd-2025-302558945.html
Sep 18, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next